ChAdOx1 nCoV-19 Vaccine Efficacy against the B.1.351 Variant. Reply.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Who cites it

16 citing papers in PubMed.

1. Targeting protein-protein interaction interfaces with antiviral N protein inhibitor in SARS-CoV-2.Biophysical journal · 2024
   Article
2. Safety and incidence of COVID-19 following ChAdOx1(AZD1222) COVID-19 vaccination in Botswana.The Journal of infection · 2023
   Article
3. Structure, dynamics and free energy studies on the effect of point mutations on SARS-CoV-2 spike protein binding with ACE2 receptor.PloS one · 2023
   Article
4. Post-Vaccination Coronavirus Disease 2019: A Case-Control Study and Genomic Analysis of 119 Breakthrough Infections in Partially Vaccinated Individuals.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022
   Article
5. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Africa: Current Considerations and Future Projections.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022
   Article
6. Effectiveness of Naturally Acquired and Vaccine-Induced Immune Responses to SARS-CoV-2 Mu Variant.Emerging infectious diseases · 2022
   Article
7. Salivary, serological, and cellular immune response to the CoronaVac vaccine in health care workers with or without previous COVID-19.Scientific reports · 2022
   Article
8. Three SARS-CoV-2 antibodies provide broad and synergistic neutralization against variants of concern, including Omicron.Cell reports · 2022
   Article
9. COVID-19 Vaccines and the Efficacy of Currently Available Vaccines Against COVID-19 Variants.Cureus · 2022
   Review
10. Resilience of Spike-Specific Immunity Induced by COVID-19 Vaccines against SARS-CoV-2 Variants.Biomedicines · 2022
    Article
11. In-depth profiling of COVID-19 risk factors and preventive measures in healthcare workers.Infection · 2022
    Article
12. Virologic Features of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Children.The Journal of infectious diseases · 2021
    Article
13. [The corona pandemic and multiple sclerosis: vaccinations and their implications for patients-Part 2: vaccine technologies].Der Nervenarzt · 2021
    Review
14. Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics.eLife · 2021
    Article
15. SARS-CoV-2 vaccines: anamnestic response in previously infected recipients.Cell research · 2021
    Article
16. SARS-CoV-2 spike therapeutic antibodies in the age of variants.The Journal of experimental medicine · 2021
    Review

Corrections and comments

• Comment on
  ChAdOx1 nCoV-19 Vaccine Efficacy against the B.1.351 Variant.2021

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as